Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Yale Launches Global Health Initiative
In an ambitious effort to further Yale University"s engagement in global health, President Richard C. Levin announced today the launch of the Yale Global Health Initiative. This is the first endeavor of the University"s new Jackson Institute of Global Affairs, which was announced in April. The purpose of the new initiative is to unite the many global health efforts across campus, foster innovative educational programs to address the growing student interest in global health, and stimulate and support faculty research to enhance healthcare around the world.
generic viagra online
Evidence-Based Information About Complementary And Alternative Medicine Treatments Now Available
More than one-third of Americans use complementary or alternative medicine (CAM). The vast majority of patients use CAM in addition to, rather than instead of, a conventional medical regimen.
News of the day
Australia's Chief Nurse Wins ICN Presidency
The Australian Nursing Federation (ANF) warmly congratulated Rosemary Bryant - Australia"s Chief Nursing and Midwifery officer - on her appointment as President of the International Council of Nurses (ICN).
Mental Health

Glenmark's Novel Molecule For Diabetes, Melogliptin To Enter Phase III Trials

In the recently completed 12 week Phase IIb clinical trial in 494 patients with type 2 diabetes mellitus (T2DM), "Melogliptin", Glenmark"s investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) inhibitors, improved glycemic control in patients with type 2 diabetes mellitus and exhibited excellent safety and tolerability profile. In addition, patients taking Melogliptin experienced low incidence of hypoglycemia and neutral effect on body weight. In this 12-week, randomized, double-blind, placebo-controlled, parallel group study, Melogliptin significantly reduced HbA1c from baseline as compared to placebo with a mean average reduction of 0.75% in patients receiving 50mg twice daily dose (p


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009